Rheumatoid Arthritis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People with active moderate to severe rheumatoid arthritis that has tested positive for certain antibodies (seropositive RA)
• People who have at least 6 tender and/or swollen joints out of 28 joints checked during the screening process (a joint that is both tender and swollen counts as 2)
• People whose rheumatoid arthritis did not respond well enough to standard disease-modifying medications (such as methotrexate), or who tried up to three biological or targeted synthetic disease-modifying medications without adequate results
• People who are currently on a stable dose of a standard disease-modifying medication as a background treatment — methotrexate must have been at a stable dose for at least 4 weeks before the study starts, and all other standard disease-modifying medications for at least 8 weeks before the study starts — and who are willing to continue that same medication throughout the 28-week study
• People who previously used certain biological or targeted synthetic disease-modifying medications, provided those medications were stopped at least 4 weeks before the study starts (or at least 8 weeks before for Golimumab or Infliximab specifically)
• People taking up to 10 mg of prednisone (a steroid) daily, provided the dose has been stable for at least 6 weeks before the study starts and they are willing to keep it stable through to the Week 24 visit
• People whose body measurement around the belly button and chest (sternum) level is between 25 and 50 inches
• People who have an immune-modulating device implanted, provided they are willing and able to turn it off at least 4 weeks before the study starts and leave it off until after the Week 24 visit
• People who are willing not to start any new treatments that affect the immune system during the study, and who have stabilised any existing immune-modulating treatments before the study begins
• People who are willing and able to follow the medication rules set out in the study's approved Medication Guide

Who may not be able to join:

• People who currently have an active bacterial or viral infection
• People who are pregnant or trying to become pregnant
• People who have received chemotherapy or immunotherapy to treat cancer within the past 30 days
• People who have previously used more than three biological or targeted synthetic disease-modifying medications in total
• People who have previously received a medication called Rituximab
• People who have an implanted device or solid object near the spleen area that could interfere with or absorb an ultrasound beam
• People who have had their spleen removed (asplenia)
• People who have a history of an enlarged spleen (splenomegaly)
• People who have a history of fluid build-up in the abdomen (ascites)
• People who have had recent abdominal surgery (confirm with trial site for specific timeframe)
• People who are currently taking part in another clinical trial involving an investigational drug or device
• People who have open wounds or sores that would make completing the study procedures too difficult
• People who are unable to perform basic daily tasks such as lifting a cup of water to their mouth or putting on clothing
• People who are unable or unwilling to regularly attend scheduled clinic visits, at-home visits, or remote video sessions
• People who cannot speak English
• People who the study investigators determine are not appropriate candidates for the trial for any other clinical reason

Important: Always verify eligibility with the trial site directly before applying.